SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Analysts and Calls -- Prudential
An SI Board Since October 2002
Posts SubjectMarks Bans
3 3 0
Emcee:  Icebrg Type:  Unmoderated
RESEARCH ALERT-Prudential raises Genentech price target
Thursday October 10, 12:00 pm ET

NEW YORK, Oct 10 (Reuters) - Prudential Securities on Thursday said it raised its stock price target for Genentech Inc. (NYSE:DNA - News) to $31 from $25 after the company reported stronger sales of cancer drugs than the brokerage had expected.

Analyst John Sonnier also raised his earnings prediction for 2002 to 91 cents a share from 90 cents, and raised his estimate for 2003 to $1.04 a share from $1.01.

Genentech reported earnings of 76 cents a share for 2001. The company reported third-quarter results after the market closed on Wednesday.

"The strong (third) quarter was due to robust sales across all product categories, each of which was slightly above our estimate," Sonnier said in a research report. "Rituxan posted an impressive $294 million in total sales versus our estimate of $285 million."

He added, "Overall, our view on Genentech remains unchanged. We continue to view Genentech as a bellwether leader in the biotech sector."

Genentech shares were off $2.12, or 6.6 percent, at $29.76 in early New York Stock Exchange trade.
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):